BMEA — Biomea Fusion, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1840439 ·
Last close
$0.49
Market Cap
$35.47M
52W High
$2.24
52W Low
$0.46
ADV30
2,125,522
Next earnings
2026-11-10
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -12,963,000 -6,183,000 28,097,000 26,403,000 20,511,000
Jun 2026 0 — -12,766,000 -8,328,000 36,873,000 34,824,000 24,736,000
Mar 2026 0 — -12,774,000 -12,415,000 46,385,000 44,693,000 27,666,000
Dec 2025 0 — -11,719,000 4,612,000 58,572,000 55,812,000 29,020,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-44,072,000
Investing CF
$550,000
Financing CF
$23,283,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.65
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-475,974,000
Inventory
—
Receivables
$22,000
ST Investments
—
EBIT TTM
$-50,222,000
Pretax Income TTM
$-22,314,000
Interest Exp TTM
—
Analysts
6

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -81,307,000 -61,797,000 58,572,000 29,020,000 29,552,000 -70,371,000
Dec 2024 0 -144,070,000 -138,426,000 79,938,000 28,365,000 51,573,000 -119,894,000
Dec 2023 0 -126,135,000 -117,255,000 199,927,000 30,690,000 169,237,000 -96,592,000
Dec 2022 0 -83,634,000 -81,828,000 129,307,000 20,768,000 108,539,000 -62,417,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-32,538,000
OpCashFlow TTM
—
Assets (Latest)
$36,873,000
Forward EPS
$-0.91

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $0.50 · spot: $0.53 · call volume: 434 · put volume: 21
Expected Move to 2027-01-15: ±$0.35 (66.04%) — implied range $0.18 – $0.88 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
OSTX OS Therapies Inc $34.86M $0.74 —
GRCE Grace Therapeutics, Inc. $36.18M $1.72 —
SER Serina Therapeutics, Inc. $36.27M $1.37 —
CNTB Connect Biopharma Holdings Ltd $36.45M $0.58 —
VERU VERU INC. $36.49M $2.14 —

News headlines (Yahoo Finance, 1h cache)

Biomea Fusion to Participate in Upcoming Investor Conferences
2026-11-12 21:01 · Yahoo
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
2026-11-10 21:05 · Yahoo
Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026
2026-11-10 12:00 · Yahoo
Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
2026-10-14 01:02 · Yahoo
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
2026-10-13 20:08 · Yahoo
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
2026-10-12 20:30 · Yahoo
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
2026-09-23 11:03 · Yahoo
Biomea Fusion Announces Proposed Public Offering of Securities
2026-09-22 20:05 · Yahoo
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
2026-09-04 13:55 · Yahoo
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
2026-08-24 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.